Список литературы

1. Эмфизема легких: Монография/Под ред. Аверьянова А.В. (Серия монографий Российского респираторного общества; Гл. ред. Серии Чучалин А.Г.). - М.: Издательский дом "Атмосфера", 2009. - 136 с.

2. Snider G.L., Kleinerman J., Thurlbeck W.M. et al. The definition of emphysema//Amer. Rev.Respir. Dis. 1985. V. 132. P. 182 - 185

3. Halbert R.J., Natoli J.L., Gano A. Global burden of COPD: systematic review and meta-analysis//Eur. Respir. J. 2006. V. 28. P. 523 - 532.

4. Mannino D.M., Gagnon R.C., Petty T.L. et al. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988 - 1994//Arch. Intern. Med. 2000 V. 160 P. 1683 - 1689

5. Hutchison DC. Alpha 1-antitrypsin deficiency in Europe: geographical distribution of Pi types S and Z. Respiratory Medicine 1998 Mar; 92(3): 367 - 77.

6. Europeanlung.org/assets/files/ru/publications/alpha1-anti-trypsin-ru.pdf. Accessed 2017 December 18.

7. Журкова Н.В., Кондакова О.Б., Строкова Т.В., Дублина Е.С., Симонова О.И., Кузьмина Л.П., Потапов А.С., Асанов А.Ю. Недостаточность 1-антитрипсина у детей с патологией печени. Педиатрия 2008; 87(3): 138 - 41.

8. Shapiro S.D., Proteolysis in the lung//Eur. Respir. J. 2003. V. 22. P. 30S - 32S.

9. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. American Journal of Respiratory and Critical Care Medicine 2003 Oct; 168(7): 818 - 900.

10. Cox DW, Woo SL, Mansfield T. DNA restriction fragments associated with antitrypsin indicate a single origin for deficiency allele PIZ. Nature 1985; 316: 79 - 81.

11. Cox DW, Billingsley GD, Mansfield T DNA restriction site polymorphisms associated with alpha 1-antitrypsin gene. American Journal of Human Genetics 1987 Nov; 41(5): 891 - 906.

12. Seixas S, Garcia O, Trovoada MJ, Santos MT, Amorim A, Rocha J. Patterns of haplotype diversity within the serpin gene cluster at 14q32.1: insights into the natural history of the alpha 1-antitrypsin polymorphism. Human Genetics 2001 Jan; 108(1): 20 - 30.

13. Keren DF. Protein electrophoresis in clinical diagnosis. London, England: Hodder Arnold; 2003: 71 - 7.

14. Brantly M, Nukiwa T, Crystal RG. Molecular basis of alpha-1-antitrypsin deficiency. The American Journal of Medicine 1988; 84(6A): 13 - 31.

15. Cox DW. Alpha-1 antitrypsin deficiency. In: The metabolic and molecular basis of inherited disease. Scriver CR, Beadet AL, Sly WS, Valle D, editors. 7^th ed. New York: McGraw-Hill; 1995: 4125 - 58.

16. Kamboh MI. Biochemical and genetic aspects of human serum proteinase inhibitor protein. Disease Markers 1985; 3:135.

17. Marciniuk DD, Hernandez P, Balter M, Bourbeau J, Chapman KR, Ford GT, Lauzon JL, Maltais F, O'Donnell DE, Goodridge D, Strange C, Cave AJ, Curren K, Muthuri S; Canadian Thoracic Society COPD Clinical Assembly Alpha-1 Antitrypsin Deficiency Expert Working Group. Alpha-1 antititrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline. Canadian Respiratory Journal 2012 Mar-Apr; 19(2): 109 - 16.

18. Churg A., Zhou S. Wright JL. Matrix metalloproteinases in COPD. The European Respiratory Journal 2012; 39(1): 197 - 209.

19. Osman M, Cantor JO, Roffman S, Keller S, Turino GM, Mandl I. Cigarette smoke impairs elastin resynthesis in lungs of hamsters with elastase-induced emphysema. The American Review of Respiratory Disease 1985 Sep; 132(3): 640 - 43.

20. Morrison HM, Kramps JA, Burnett D, Stockley RA. Lung lavage fluid from patients with proteinase inhibitor deficiency or chronic obstructive bronchitis: anti-elastase function and cell profile. Clinical Science (London) 1987 Mar; 72(3): 373 - 81.

21. Satoh K., Kobayashi T., Misao T. CT assessment of subtypes of pulmonary emphysema in smokers//Chest 2001 V. 120 P. 725 - 729.

22. Hobbs BD, Foreman MG, Bowler R, Jacobson F, Make BJ, Castaldi PJ, et al. COPDGene Investigators. Pneumothorax risk factors in smokers with and without chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014; 11: 1387 - 1394.

23. Гембицкая Т.Е., Черменский А.Г., Илькович М.М., Цампруби С. Первичная эмфизема легких у молодого мужчины, обусловленная гомозиготным дефицитом (генотип ZZ): перспективы организации помощи больным. Пульмонология 2014; 6: 115 - 21.

24. Shin MS, Ho KJ. Bronchiectasis in patients with antitrypsin deficiency. A rare occurrence? Chest 1993 Nov; 104(5): 1384 - 6.

25. Eden E, Mitchell D, Mehlman B, Khouli H, Mejat M, Grieco MH, Turino GM. Atopy, asthma and emphysema in patients with severe deficiency. American Journal of Respiratory and Critical Care Medicine 1997 Jul; 156(1): 68 - 74.

26. Higgins MW, Thom T. Incidence, prevalence and mortality: intra- and inter country differences. In: Clinical epidemiology of chronic obstructive pulmonary disease. Hensley MJ, Saunders NA, editors. New York: Marcel Dekker; 1989: 23 - 43.

27. Eriksson S. Alpha-1 antitrypsin deficiency: natural course and therapeutic strategies. In: Proceedings of the Falk Symposium no. 115. Dordrecht, The Netherlands. Dordrecht/Boston/London: Kluwer Academic Publishers; 1999: 307 - 15.

28. Han MK, Tayob N, Murray S, Woodruff PG, Curtis JL, Kim V, et al. COPDGene and SPIROMICS Investigators. Association between emphysema and chronic obstructive pulmonary disease outcomes in the COPDGene and SPIROMICS cohorts: a post hoc analysis of two clinical trials. Am J Respir Crit Care Med. 2018; 198: 265 - 267.

29. Sinden NJ, Stockley RA. Proteinase 3 activity in sputum from subjects with alpha-1-antitrypsin deficiency and COPD. The European Respiratory Journal 2013; 41(5): 1042 - 50.

30. Stoller JK, Smith P, Yang P, Spray J. Physical and social impact of antitrypsin deficiency: results of a survey. Cleveland Clinic Journal of Medicine 1994 Nov-Dec; 61(6): 461 - 7.

31. IC, Bakke P, Gulsvik A, Pillai SG, Johannessen A, Gaarder PI, Campbell EJ, A, Calverley PM, Donner CF, Make BJ, Rennard SI, Vestbo J, Wouters EF, PD, Levy RD, Coxson HO, Lomas DA, Hersh CP, Silverman EK. antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts. Chest 2010 Nov; 138(5): 1125 - 32.

32. Owen MC, Brennan SO, Lewis JH, Carrell RW. Mutation of antitrypsin to antithrombin alpha 1-antitrypsin Pittsburgh (358 Met leads toArg), a fatal bleeding disorder. The New England Journal of Medicine 1983 Sep; 309(12): 694 - 8.

33. Kohansal R, Martinez-Camblor P, A, Buist AS, Mannino DM, Soriano JB. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med. 2009 Jul 1; 180(1): 3 - 10. doi: 10.1164/rccm.200901-0047OC. Epub 2009 Apr 2. PMID: 19342411.

34. Мельник С.И., Власов Н.Н., Пиневская М.В., Орлова Е.А., Старевская Е.В., Мельникова И.Ю. Дефицит альфа-1-антитрипсина у детей: описание серии случаев. Вопросы современной педиатрии 2016; 15(6): 619 - 24.

35. Elzouki AN, Eriksson S. Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma? European Journal of Gastroenterology & Hepatology 1996; Oct; 8(10): 989 - 94.

36. Eriksson S, Carison J, Velez R. Risks for cirrhosis and primary liver cancer in antitrypsin deficiency. The New England Journal of Medicine 1986 Mar; 314(12): 736 - 9.

37. O'Riordan K, Blei A, Rao MS, Abecassis M. Alpha-1 antitrypsin deficiency-associated panniculitis: resolution with intravenosus antitrypsin and liver transplantation. Transplantation 1997 Feb; 63(3): 480 - 2.

38. Zorzetto M, Russi E, Senn O, Imboden M, Ferrarotti I, Tinelli C, Campo I, Ottaviani S, Scabini R, von Eckardstein A, Berger W, O, Rochat T, Luisetti M, Probst-Hensch N; SAPALDIA Team. SERPINA 1 gene variants in individuals from the general population with reduced alpha 1-antitrypsin concentrations. Clinical Chemistry 2008 Aug; 54(8): 1331 - 8.

39. Miravitlles M, Herr C, Ferrarotti I, Jardi R, Rodriguez-Frias F, Luisetti M, Bals R. Laboratory testing of individuals with severe alpha 1-antitrypsin deficiency in three European centers. The European Respiratory Journal 2010 May; 35(5): 960 - 8.

40. Bornhorst JA, Greene CM, Ashwood ER., Greenache DG. phenotypes and associated serum protein concentrations in a large clinical population. Chest 2013 Apr; 143(4): 1000 - 8.

41. Guerra S., Sherrill D., Bobadilla A. et al. The relation of body mass index to asthma, chronic bronchitis and emphysema//Chest 2002V. 122 P. 1256 - 1263.

42. Amalakanti S, Pentakota MR Pulse Oximetry Overestimates Oxygen Saturtion in COPD//Respir Care 2016; 61 (4): 423 - 7.

43. Gishen P, Saunders AJS, Tobin MJ, Hutchison DCS. Alpha-1 antitrypsin deficiency: the radiological features of pulmonary emphysema in subjects of Pi-type-Z and Pi-type-SZ. A survey by the British Thoracic Association. Clin Radiol 1982; 33: 371 - 377.

44. Foster WL Jr, Gimenez EI, Roubidoux MA, Sherrier RH, Shannon RH, Roggli VL, Pratt PC. The emphysemas: radiologic-pathologic correlations. Radiographics 1993; 13: 311 - 328.

45. Dawwas MF, Davies SE, Griffiths WJ et al. Prevalence and risk factors for liver involvement in individuals with PiZZ-related lung disease. Am J Respir Crit Care Med. 2013; 187(5): 502 - 508.

46. Crowther DC, Belogrey D, Miranda E, Kinghorn KJ, Sharp LK, Lomas DA. Practical genetics: alpha-1-antitrypsin deficiency and the serpinopathies. European Journal of Human Genetics 2004 Mar; 12(3): 167 - 72.

47. Nelson DR, Teckman J, Di Bisceglie AM et al. Diagnosis and management of patients with alpha 1-antitrypsi

48. Sandhaus RA. Alpha 1-antitrypsin deficiency: whom to test, whom to treat? Seminars in Respiratory and Critical Care Medicine 2010 Jun; 31(3): 343 - 7.

49. Dowson LJ, Guest PJ, Hill SL, Holder RL, Stockley RA. High-resolution computed tomography scanning in alpha 1-antitrypsin deficiency: relationship to lung function and health status. The European Respiratory Journal 2001 Jun; 17(6): 1097 - 104.

50. Gevenois P.A., de Maertelaer V/. de Vuyst P. et al. Comparison of computed density and macroscopic morphometry in pulmonary emphysema//Amer. J. Respir. Crit. Care Med. 1995 V. 152 P. 653 - 700.

51. Parr DG, Stoel BC, Stolk J, Stockley RA. Validation of computed tomography lung densitometry for monitoring emphysema alpha 1-antitrypsin deficiency. Thorax 2006 Jun; 61(6): 485 - 90.

52. Dirksen A, Friis M, Olesen KP, Skovgaard LT, Sorensen K. Progress of emphysema in severe -1 antitrypsin deficiency as assessed by annual CT. Acta Radiol 1997; 38: 826 - 832

53. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2019//www.goldcopd.com.

54. Hill K, Goldstein RS, Guyatt GH et al. Prevalence and underdiagnosis of chronic obstructive pulmonary diseaseamong patients at risk im primary care//CMAJ 2010; 182(7): 673 - 8.

55. Quanjer PH, Tammeling GJ, Cotes JE et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European 80 Community for Steel and Coal. Official Statement of the European Respiratory Society//Eur Respir J. 1993, 6: suppl. 16, 5 - 40.

56. Wanger J, Clausen JL, Coates A et al. Standardisation of the measurement of lung volumes//Eur Respir J 2005; 26: 511 - 522.

57. Sanders C., Nath P.H., Bailey W. Detection of emphysema with computed tomography: correlation with pulmonary function tests and chest radiography//Invest. Radiol. 1988 V. 23 P. 262 - 266.

58. Функциональная диагностика в пульмонологии: Практическое руководство/Под ред. Чучалина А.Г. - М.: Издательский холдинг "Атмосфера", 2009. - 192 с.

59. Lomas DA. Genetic predisposition to chronic obstructive pulmonary disease: advances in alpha 1-antitrypsin deficiency and serpinopathies. Clinical Medicine 2007; 7(5): 446 - 7.

60. Tanash HA, Nilsson PM, Nilsson JA et al. Clinical course and prognosis of never-smokers with severe alpha 1-antitrypsin deficiency (PiZZ). Thorax. 2008; 63(12): 1091 - 1095.

61. Pelkonen M, Notkola IL, Tukiainen H, Tervahauta M, Toumilehto J, Nissinen A: Smoking cessation, decline in pulmonary function and total mortality: a 30-year follow-up study among the Finnish cohorts of the Seven Countries Study. Thorax 2001; 56: 703 - 707.

62. Chandler MA, Rennard SI: Smoking cessation. Chest 2010; 137: 428 - 435.

63. Henningfield JE: Nicotine medications for smoking cessation. N Engl J Med 1995; 333: 1196 - 1203.

64. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685 - 691.

65. Silagy C, Mant D, Fowler G, Lodge M: Metaanalysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994; 343: 139 - 142.

66. Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, Gonzales D, Dozier G, Patel MK, Jamerson B: Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571 - 1575.

67. Strassmann R, Bausch B, Spaar A, Kleijnen J, Braendli O, Puhan MA: Smoking cessation interventions in COPD: a network metaanalysis of randomised trials. Eur Respir J 2009; 34: 634 - 640.

68. Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchinson DC, Ulrik CS, Skovgaard LT, Kok-Jensen A, Rudolphus A, Seersholm N, Vrooman HA, Reiber JH, Hansen NC, Heckscher T, Viskum K, Stolk J. A randomized clinical trial of antitrypsin augmentation therapy. American Journal of Respiratory and Critical Care Medicine 1999 Nov; 160(5 Pt 5): 1468 - 72.

69. Dirksen A., Piitulainen E, Parr DG, Deng C, Wencker M, Shaker SB, Stockley RA. Exploring the role of CT densitometry: a randomized study of augmentation therapy in alpha1-antitrypsin deficiency. The European Respiratory Journal 2009 Jun; 33(6): 1345 - 53.

70. Chapman KR, Stockley RA, Dawkins C, Wilkes MM, Navickis RJ. Augmentation therapy for alpha1-antitrypsin deficiency: a meta-analysis. COPD 2009 Jun; 6(3): 177 - 84.

71. Gotzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. The Cochrane Database of Systematic Reviews 2010 Jul; 7(7): CD007851.

72. McElvaney NG, Burdon J, Holmes M, Glanville A, Wark PA, Thompson PJ, Hernandez P, Chlumsky J, Teschler H, Ficker JH, Seersholm N, Altraja A, R, Chorostowska-Wynimko J, Sanak M, Stoicescu PI, Piitulainen E, Vit O, Wencker M, Tortorici MA, Fries M, Edelman JM, Chapman KR; RAPID Extension Trial Group. Long-term efficacy and safety of alpha 1 proteinase inhibitor treatment for emphysema caused by severe alpha 1-antitrypsin deficiency: an open-label extension trial (RAPID-OLE). The Lancet Respiratory Medicine 2017 Jan; 5(1): 51 - 60.

73. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha 1-antitrypsin. American Journal of Respiratory and Critical Care Medicine 1998; 127(Suppl): S43 - S45.

74. Seersholm N, Wencker M, Banik N, Viskum K, Dirsken A, Kok-Jensen A, Konietzko N. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. The European Respiratory Journal 1997 Oct; 10(10): 2260 - 3.

75. Wencker M, Banik N, Buhl R, Seidel R, Konietzko N. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group. The European Respiratory Journal 1998 Feb; 11(2); 428 - 33.

76. JC, Torres ML, Blanco I, MT; Investigators of the rEXA study group. Reduction of severe exacerbations and hospitalization-derived costs in alpha 1-antitrypsin-deficient patients treated with alpha 1-antitrypsin augmentation therapy. Therapeutic Advances in Respiratory Disease 2012 Apr; 6(2): 67 - 78.

77. Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 2000 Nov; 118(5): 1480 - 5.

78. Rahaghi FF, Miravitlles M. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha 1-antitrypsin deficiency: a look at the evidence. Respiratory Research 2017 May; 18(1): 105.

79. Balbi B, Ferrarotti I, Miravitlles M. Efficacy of augmentation therapy for emphysema associated with 1-antitrypsin deficiency: enough is enough. The European Respiratory Journal 2016 Jan: 47(1): 35 - 8.

80. Prins J, van der Meijden B, Kraaijeenhangen RJ, Wielders JP. Inherited chronic obstructive pulmonary disease: new selective-sequencing workup for alpha1-antitrypsin deficiency identifies 2 previously unidentified null alleles. Clinical Chemistry 2008 Jan; 54(1): 101 - 7.

81. Brantly ML, Lascano JE, Shahmohammadi A. Intravenous alpha-1 antitrypsin therapy for alpha-1 antitrypsin deficiency: the current state of the evidence. Chronic Obstr Pulm Dis. 2019; 6(1): 100 - 114. doi: https://doi.org/10.15326/jcopdf.6.1.2017.0185

82. Sandhaus RA, Turino G, Brantly ML et al. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult//Journal of the COPD Foundation 2016 Vol 3 N 3 P 668 - 682.

83. Molloy K, Hersh CP, Morris VB et al. Clarification of the risk of chronic obstructive pulmonary disease in alpha-1 antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med. 2014; 189(4): 419 - 427.

84. Campos MA, Kueppers F, Stocks JM et al. Safety and pharmacokinetics of 120mg/kg versus 60 mg/kg weekly intravenous infusions of alpha -1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK). COPD. 2013; 10(6): 687 - 695

85. Meyer FJ, Wencker M, Teschler H, Steveling H, Sennekamp J, Costbel U, Konietzko N. Acute allergic reaction and demonstration of specific IgE antibodies against alpha-1-protease inhibitor. The European Respiratory Journal 1998; 12(4): 996 - 7.

86. Stoller JK, Fallat R, Schluchter MD, O'Brien RG, Connor JT, Gross N, O'Neil K, Sandhaus R, Crystal RG. Augmentation therapy with alpha 1 antitrypsin: patterns of use and adverse events. Chest 2003 May; 123(5): 1425 - 34.

87. Eden E, Holbrook JT, Brantly ML, Turino GM, Wise RA. Prevalence of alpha-1 antitrypsin deficiency in poorly controlled asthma - results from the ALA-ACRC low dose theophylline trial. Journal of Asthma 2007 Oct; 44(8): 605 - 8.

88. Ngo LY, Haeberle A, Dyck-Jones J, Gelmont D, Yel L. Safety and tolerability of an intravenously administered alpha1-proteinase inhibitor at an increased infusion rate: a novel, randomized, placebo-masked, infusion rate-controlled, crossover study in healthy adults. Open Access Journal of Clinical Trials 2014 Jun; 6: 55 - 61.

89. Stoller JK, Panos RJ, Krachman S. et al. Oxygen therapy for patients with COPD: current evidence and the long-term oxygen treatment trial//Chest 2010; 138: 179 - 87

90. Moore RP, Berlowitz DJ, Denehy L. et al. A randomized trial of domiciliary, ambulatory oxygen tin patients with COPD and dyspnea but without resting hypoxaemia//Thorax 2011; 66: 32 - 7

91. Naunheim KS, Wood DE, Mohsenifar Z et al. Long-term follow-up of patients receiving lung-volume reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group//Ann Thorac Surg 2006; 82: 431 - 43.

92. Николаев Г.В., Вардамов В.В., Яблонский П.К. и др. Хирургическая редукция объема легких у больных с диффузной эмфиземой//Вестн. Хирургии им. И.И. Грекова 2003 Т. 162 N 2 С. 21 - 24.

93. Flaherty K.R., Martinez F.J. Lung volume reduction surgery for emphysema//Clin. Chest Med. 2000 V. 21 N 4 P. 819 - 848.

94. Cassina PC, Teschler H Konietzko N, Theegarten D, Stamatis G. Two-year results after lung volume reduction surgery in alpha1-antitrypsin deficiency versus smoker's emphysema. The European Respiratory Journal 1998 Nov; 12(5): 1028 - 32.

95. Gelb AF, McKenna RJ, Brenner M, Fischel R, Zamel N. Lung function after bilateral lower lobe lung volume reduction surgery for alpha1-antitrypsin emphysema. The European Respiratory Journal 1999 Oct; 14(4): 928 - 33.

96. National Emphysema Treatment Trial Research Group, Fishman A, Fessler H, Martinez F, McKenna RJ Jr, Naunheim K, Piantadosi S, Weinmann G, Wise R. Patients at high risk of death after lung-volume-reduction surgery. The New England Journal of Medicine 2001 Oct; 345(15): 1075 - 83.

97. Hosenpud JD, Novick RJ, Breen TJ, Keck B, Daily P. Registry of the International Society for Heart and Lung Transplantation: twelfth official report - 1995. The Journal of Heart and Lung Transplantation 1995 Sep-Oct; 14(5): 805 - 15.

98. Banga A, Gildea T, Rajeswaran J et al. The natural history of lung function after lung transplantation for alpha (1)-antitrypsin deficiency. Am J Respir Crit Care Med. 2014; 190(3): 274 - 281.

99. Yusen RD, Edward LB, Kucheryavaya MS et al. The registry of the International Society of Heart and Lung Transplantation; Thirty-second official adult lung and heart-lung transplantation report 2015. J Heart Lung Transplant. 2015; 34(10): 1264 - 1277.

100. Nici L., Donner C., Wouters E., et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006; 173: 1390 - 413.

101. Ries A.L., Bauldoff G.S., Carlin B.W., et al. Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest 2007; 131: 4S - 42S.

102. Celli B.R. Pulmonary rehabilitation in patients with COPD. Am J Respir Crit Care Med 1995; 152: 861 - 4.

103. Troosters T., Casaburi R., Gosselink R., Decramer M. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 19 - 38.

104. Puhan M.A., Busching G., Schunemann H.J., VanOort E., Zaugg C., Frey M. Interval versus continuous high-intensity exercise in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2006; 145: 816 - 25.

105. Mahler D.A., Pulmonary rehabilitation. Chest 1998; 113: 263S - 8S.

106. Belman M.J., Botnick W.C., Nathan S.D., Chon K.H. Ventilatory load characteristics during ventilatory muscle training. Am J Respir Crit Care Med 1994; 149: 925 - 9.

107. O'Brien K., Geddes E.L., Reid W.D., Brooks D., Crowe J. Inspiratory muscle training compared with other rehabilitation interventions in chronic obstructive pulmonary disease: a systematic review update. J Cardiopulm Rehabil Prev 2008; 28: 128 - 41.

108. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA Jr, Enright PL, Kanner RE, O'Hara P. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilatator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994 Nov; 272(19): 1497 - 505.

109. Heffner J.E., Fahy B., Hilling L., Barbieri C.: Outcomes of advance directive education of pulmonary rehabilitation patients. Am J Respir Crit Care Med 1997; 155: 1055 - 1059.

110. Stewart M.A.: Effective ph Heffner J.E., Fahy B., Hilling L., Barbieri C.: Outcomes of advance directive education of pulmonary rehabilitation patients. Am J Respir Crit Care Med 1997; 155: 1055 - 1059.

111. Carpenter MJ,Strange C, Jones Y et al. Does genetic testing result in behavioral health change? Ann. Behav.Med. 2007; 33(1): 22 - 28

112. Walters JA, Smith S, Poole P, Granger RH, Wood-Baker R. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2010; 11: CD001390.

113. Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 1: CD002733

114. Kuller JA, Katz VL, McCoy MC, Bristow CL. Alpha-1 antitrypsin deficiency and pregnancy. American Journal of Perinatology 1995 Sep; 12(5): 303 - 5.

115. Atkinson AR. Pregnancy and alpha-1 antitrypsin deficiency. Postgraduate Medical Journal 1987 Sep; 63(743): 817 - 20.

116. Geisler CF, Buehler JH, Depp R. Alpha-1 antitrypsin deficiency: severe obstructive lung disease and pregnancy. Obstetrics & Gynecology 1977; 49(1): 31 - 4.

117. Ranes J, Stoller JK. A review of alpha 1-antitrypsin deficiency. Seminars in Respiratory and Critical Care Medicine 2005 Apr; 26(2): 154 - 66.

118. Hall JC, Tarala RA, Hall JL, Mander J. A multivariate analysis of the risk of pulmonary complications after laparotomy. Chest 1991 Apr; 99(4): 923 - 7.

119. Amalakanti S., Pentakota M. R. Pulse oximetry overestimates oxygen saturation in COPD//Respiratory care. - 2016. - Т. 61. - N. 4. - С. 423 - 427.